missing translation for 'onlineSavingsMsg'
Learn More
Learn More
R&D Systems™ Recombinant Human IL-29/IFN-lambda 1 Protein
E. coli-expressed
Marke: R&D Systems™ 11240-IL-050
Dieser Artikel kann nicht zurückgegeben werden.
Rückgaberichtlinie anzeigen
Beschreibung
Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED50 for this effect is 0.500-6.00 ng/mL.Spezifikation
| Q8IU54.1 | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. | |
| M.W. Observed: 18-22 kDa, under reducing conditions., M.W. Theoretical: 20 kDa | |
| E. coli-derived human IL-29/IFN-lambda 1 protein Pro23-Thr200 | |
| <0.10 EU per 1 μg of the protein by the LAL method. | |
| Unconjugated | |
| >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. |
| Bioactivity | |
| 282618 | |
| 50 μg | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution. | |
| cytokine Zcyto21, IFNL1, IFN-lambda 1, IFN-lambda-1, IL29, IL-29, interferon lambda-1, interferon, lambda 1, interleukin 29 (interferon, lambda 1), interleukin-29, ZCYTO21 | |
| Reconstitute at 500 μg/mL in PBS. | |
| IL-29/IFN-lambda 1 |
Berichtigung von Produktinhalten
Bitte geben Sie uns Ihr Feedback zu den Produktinhalten, indem Sie das folgende Formular ausfüllen.
Name des Produkts
Haben Sie Verbesserungsvorschläge?Übermitteln Sie eine inhaltliche Korrektur